Wolverine Trading, LLC Tg Therapeutics, Inc. Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $745,193 - $1.09 Million	43,300 Added 34.92%	167,300 $3.91 Million
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $182,484 - $262,903	13,700 Added 12.42%	124,000 $2.21 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $1 Million - $1.64 Million	-77,100 Reduced 41.14%	110,300 $1.68 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $363,392 - $1.02 Million	54,400 Added 40.9%	187,400 $3.2 Million
Q3 2023 Nov 15, 2023	SELL	$8.36 - $26.5 $521,663 - $1.65 Million	-62,400 Reduced 31.93%	133,000 $1.11 Million
Q2 2023 Aug 23, 2023	BUY	$15.48 - $35.0 $1.69 Million - $3.83 Million	109,400 Added 127.21%	195,400 $4.85 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $879,780 - $1.66 Million	86,000 New	86,000 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $31,533 - $57,960	6,900 Added 18.21%	44,800 $268,000
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $32,164 - $91,676	-8,600 Reduced 18.49%	37,900 $164,000
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $194,469 - $509,205	-24,900 Reduced 34.87%	46,500 $457,000
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $241,680 - $564,609	15,900 Added 28.65%	71,400 $1.38 Million
Q3 2021 Nov 12, 2021	BUY	$21.78 - $40.45 $326,700 - $606,750	15,000 Added 37.04%	55,500 $1.86 Million
Q2 2021 Aug 06, 2021	BUY	$32.5 - $48.96 $227,500 - $342,720	7,000 Added 20.9%	40,500 $1.52 Million
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $2.34 Million - $3.05 Million	-56,200 Reduced 62.65%	33,500 $1.52 Million
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $318,402 - $691,740	12,600 Added 16.34%	89,700 $4.74 Million
Q3 2020 Nov 13, 2020	SELL	$18.49 - $27.24 $430,816 - $634,692	-23,300 Reduced 23.21%	77,100 $2.02 Million
Q2 2020 Aug 13, 2020	SELL	$8.9 - $21.84 $826,810 - $2.03 Million	-92,900 Reduced 48.06%	100,400 $1.87 Million
Q1 2020 May 11, 2020	SELL	$7.14 - $15.99 $12,852 - $28,782	-1,800 Reduced 0.92%	193,300 $2 Million
Q4 2019 Feb 12, 2020	BUY	$5.1 - $11.2 $391,680 - $860,160	76,800 Added 64.92%	195,100 $2.12 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $207,130 - $346,115	38,500 Added 48.25%	118,300 $668,000
Q2 2019 Aug 20, 2019	BUY	$6.27 - $8.65 $20,691 - $28,545	3,300 Added 4.31%	79,800 $690,000
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $440,993 - $881,987	-109,700 Reduced 58.92%	76,500 $615,000
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $99,416 - $166,464	-28,900 Reduced 13.44%	186,200 $741,000
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $20,600 - $56,000	4,000 Added 1.89%	215,100 $1.21 Million
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $1.84 Million - $3.55 Million	211,100 New	211,100 $3 Million
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $867,300 - $1.45 Million	-118,000 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$10.0 - $12.7 $1.18 Million - $1.5 Million	118,000	118,000 $1.4 Million

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

87.7M

Call Options Held

2.35M

Put Options Held

1.7M

Vanguard Group Inc Valley Forge, PA

15.4M
Shares

$495 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$367 Million
0.0% of portfolio
State Street Corp Boston, MA

9.09M
Shares

$293 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

3.58M
Shares

$115 Million
0.1% of portfolio
Geode Capital Management, LLC Boston, MA

3.21M
Shares

$103 Million
0.01% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.68B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account